Key result
Rapid bedside measurement of B-type natriuretic peptide in patients with acute dyspnea reduced median time to discharge (8.0 vs 11.0 days, P=0.001) and mean total cost ($5,410 vs $7,264, P=0.006).
Why the study?
Does a diagnostic strategy involving the measurement of B-type natriuretic peptide levels reduce time to discharge and total cost of treatment in patients presenting to the emergency department with acute dyspnea?
RCT (n=452)
Does a diagnostic strategy involving the measurement of B-type natriuretic peptide levels reduce time to discharge and total cost of treatment in patients presenting to the emergency department with acute dyspnea?
Absolute Event Rate: 8% vs 11%
p-value: p=0.001
Rapid bedside measurement of B-type natriuretic peptide in patients presenting to the emergency department with acute dyspnea significantly reduces time to discharge, hospitalization rates, and total treatment costs.
No takes yet. Share an insight, caveat, or question.
Supports bedside BNP testing in acute dyspnea ED pathways; extends evidence with RCT confirmation of efficiency gains.
Mueller et al. (2004) conducted an RCT in Acute dyspnea (n=452). Diagnostic strategy involving rapid bedside assay of B-type natriuretic peptide (BNP) vs. Standard assessment was evaluated on Time to discharge (median days) (p=0.001). Rapid bedside measurement of B-type natriuretic peptide in patients with acute dyspnea reduced median time to discharge (8.0 vs 11.0 days, P=0.001) and mean total cost ($5,410 vs $7,264, P=0.006).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: